Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01712490




Registration number
NCT01712490
Ethics application status
Date submitted
19/10/2012
Date registered
23/10/2012
Date last updated
20/02/2024

Titles & IDs
Public title
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
Scientific title
A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma
Secondary ID [1] 0 0
2011-005450-60
Secondary ID [2] 0 0
C25003
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hodgkin Lymphoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Cancer 0 0 0 0
Hodgkin's

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - brentuximab vedotin
Treatment: Drugs - doxorubicin
Treatment: Drugs - bleomycin
Treatment: Drugs - vinblastine
Treatment: Drugs - dacarbazine

Experimental: A + AVD - A+AVD consists of brentuximab vedotin (ADCETRIS®) 1.2 milligram per kilogram (mg/kg) plus doxorubicin 25 milligram per square meter (mg/m^2), vinblastine 6 mg/m^2, and dacarbazine (DTIC) 375 mg/m^2.

Active Comparator: ABVD - ABVD consists of doxorubicin 25 mg/m^2, bleomycin 10 units per square meter (units/m^2), vinblastine 6 mg/m^2, and dacarbazine (DTIC) 375 mg/m^2.


Treatment: Drugs: brentuximab vedotin
Brentuximab vedotin (ADCETRIS®)1.2 mg/kg by IV infusion on Days 1 and 15 of each 28-day cycle.

Treatment: Drugs: doxorubicin
Doxorubicin: 25 mg/m^2 by IV infusion on Days 1 and 15 of each 28-day cycle.

Treatment: Drugs: bleomycin
Bleomycin: 10 units/m^2 by IV infusion on Days 1 and 15 of each 28-day cycle.

Treatment: Drugs: vinblastine
Vinblastine: 6 mg/m2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle

Treatment: Drugs: dacarbazine
Dacarbazine (DTIC): 375 mg/m^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Modified Progression-free Survival (mPFS) Per Independent Review Facility (IRF)
Timepoint [1] 0 0
Baseline until PD or death or receipt of any subsequent anticancer therapy for HL after completion of frontline therapy (approximately up to 4 years)
Secondary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
Baseline until death (approximately up to 4 years)
Secondary outcome [2] 0 0
Complete Remission (CR) Rate at the End of Randomized Regimen Per IRF
Timepoint [2] 0 0
Baseline up to end of randomized regimen (approximately 1 year)
Secondary outcome [3] 0 0
Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)
Timepoint [3] 0 0
Baseline up to 30 days after last dose of study drug (approximately 1 year)
Secondary outcome [4] 0 0
Number of Participants With Abnormal Clinical Laboratory Values
Timepoint [4] 0 0
Baseline up to 30 days after last dose of study drug (approximately 1 year)
Secondary outcome [5] 0 0
Event-free Survival (EFS) Per IRF
Timepoint [5] 0 0
Baseline until PD or discontinuation of treatment or death, whichever occurs first (approximately up to 4 years)
Secondary outcome [6] 0 0
Disease-free Survival (DFS) Per IRF
Timepoint [6] 0 0
From CR until PD or death (approximately up to 4 years)
Secondary outcome [7] 0 0
Overall Response Rate (ORR) Per IRF
Timepoint [7] 0 0
Baseline up to end of randomized regimen (approximately 1 year)
Secondary outcome [8] 0 0
Duration of Response (DOR) Per IRF
Timepoint [8] 0 0
From first documented response until PD (approximately 4 years)
Secondary outcome [9] 0 0
Duration of Complete Remission (DOCR) Per IRF
Timepoint [9] 0 0
From first documentation of CR until PD (approximately 4 years)
Secondary outcome [10] 0 0
Percentage of Participants Not in CR Per IRF Who Received Subsequent Radiation After Completion of Frontline Therapy
Timepoint [10] 0 0
Baseline up to end of frontline therapy (approximately 4 years)
Secondary outcome [11] 0 0
Complete Remission (CR) Per IRF Rate at the End of Frontline Therapy
Timepoint [11] 0 0
Baseline up to end of frontline therapy (approximately 4 years)
Secondary outcome [12] 0 0
Positron Emission Tomography (PET) Negativity Rate Per IRF at Cycle 2
Timepoint [12] 0 0
Cycle 2 Day 25
Secondary outcome [13] 0 0
A+AVD: Cmax: Maximum Observed Serum Concentration for Brentuximab Vedotin Antibody-drug Conjugate (ADC) and Total Antibody (TAb)
Timepoint [13] 0 0
Cycle 1 Day 1 and Cycle 3 Day 1: pre-dose and at multiple timepoints (up to 48 hours) post-dose
Secondary outcome [14] 0 0
A+AVD: Cmax: Maximum Observed Plasma Concentration for Brentuximab Vedotin Monomethyl Auristatin E (MMAE)
Timepoint [14] 0 0
Cycle 1 Day 1 and Cycle 3 Day 1: pre-dose and at multiple timepoints (up to 48 hours) post-dose
Secondary outcome [15] 0 0
A+AVD: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Brentuximab Vedotin ADC and TAb
Timepoint [15] 0 0
Cycle 1 Day 1: pre-dose and at multiple timepoints (up to 48 hours) post-dose
Secondary outcome [16] 0 0
A+AVD: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Brentuximab Vedotin MMAE
Timepoint [16] 0 0
Cycle 1 Day 1: pre-dose and at multiple timepoints (up to 48 hours) post-dose
Secondary outcome [17] 0 0
A+AVD: Number of Participants With Antitherapeutic Antibody (ATA) and Neutralizing Antitherapeutic Antibody (nATA) Positive for Brentuximab Vedotin
Timepoint [17] 0 0
Baseline up to end of treatment (approximately 1 year)
Secondary outcome [18] 0 0
Change From Baseline in Patient-Reported Outcome (PRO) Scores by mPFS Based on European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-C30 (EORTC QLQ-C30) at EOT
Timepoint [18] 0 0
Baseline up to end of treatment (approximately 1 year)

Eligibility
Key inclusion criteria
1. Treatment-naïve participants with Ann Arbor Stage III or IV HL.

2. Histologically confirmed classical Hodgkin Lymphoma (HL) according to the current
World Health Organization (WHO) classification.

3. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to
(<=) 2.

4. Bidimensional measurable disease as documented by radiographic technique per the
International Working Group Revised Criteria for Response Assessment for Malignant
Lymphoma.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Nodular lymphocyte predominant Hodgkin lymphoma.

2. Cerebral/meningeal disease, including signs and symptoms of progressive
multifocalleukoencephalopathy (PML).

3. Sensory or motor peripheral neuropathy.

4. Prior immunosuppressive chemotherapy, therapeutic radiation, or any immunotherapy
within 12 weeks of first study drug dose.

5. Known human immunodeficiency virus (HIV) positive.

6. Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C
infection.

Please note that there are additional exclusion criteria. The study center will determine
if you meet all of the criteria.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
9/11/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
13/01/2026
Actual
Sample size
Target
Accrual to date
Final
1334
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,VIC,WA
Recruitment hospital [1] 0 0
- Kingswood
Recruitment hospital [2] 0 0
- St Leonards
Recruitment hospital [3] 0 0
- Westmead
Recruitment hospital [4] 0 0
- South Brisbane
Recruitment hospital [5] 0 0
- Bedford Park
Recruitment hospital [6] 0 0
- Hobart
Recruitment hospital [7] 0 0
- East Melbourne
Recruitment hospital [8] 0 0
- Geelong
Recruitment hospital [9] 0 0
- Heidelberg
Recruitment hospital [10] 0 0
- Parkville
Recruitment hospital [11] 0 0
- Perth
Recruitment postcode(s) [1] 0 0
- Kingswood
Recruitment postcode(s) [2] 0 0
- St Leonards
Recruitment postcode(s) [3] 0 0
- Westmead
Recruitment postcode(s) [4] 0 0
- South Brisbane
Recruitment postcode(s) [5] 0 0
- Bedford Park
Recruitment postcode(s) [6] 0 0
- Hobart
Recruitment postcode(s) [7] 0 0
- East Melbourne
Recruitment postcode(s) [8] 0 0
- Geelong
Recruitment postcode(s) [9] 0 0
- Heidelberg
Recruitment postcode(s) [10] 0 0
- Parkville
Recruitment postcode(s) [11] 0 0
- Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Indiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Iowa
Country [11] 0 0
United States of America
State/province [11] 0 0
Kansas
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
Minnesota
Country [16] 0 0
United States of America
State/province [16] 0 0
Missouri
Country [17] 0 0
United States of America
State/province [17] 0 0
Nebraska
Country [18] 0 0
United States of America
State/province [18] 0 0
Nevada
Country [19] 0 0
United States of America
State/province [19] 0 0
New Jersey
Country [20] 0 0
United States of America
State/province [20] 0 0
New Mexico
Country [21] 0 0
United States of America
State/province [21] 0 0
New York
Country [22] 0 0
United States of America
State/province [22] 0 0
North Carolina
Country [23] 0 0
United States of America
State/province [23] 0 0
North Dakota
Country [24] 0 0
United States of America
State/province [24] 0 0
Ohio
Country [25] 0 0
United States of America
State/province [25] 0 0
Oklahoma
Country [26] 0 0
United States of America
State/province [26] 0 0
Oregon
Country [27] 0 0
United States of America
State/province [27] 0 0
Pennsylvania
Country [28] 0 0
United States of America
State/province [28] 0 0
South Carolina
Country [29] 0 0
United States of America
State/province [29] 0 0
Tennessee
Country [30] 0 0
United States of America
State/province [30] 0 0
Texas
Country [31] 0 0
United States of America
State/province [31] 0 0
Utah
Country [32] 0 0
United States of America
State/province [32] 0 0
Virginia
Country [33] 0 0
United States of America
State/province [33] 0 0
Washington
Country [34] 0 0
United States of America
State/province [34] 0 0
West Virginia
Country [35] 0 0
United States of America
State/province [35] 0 0
Wisconsin
Country [36] 0 0
Belgium
State/province [36] 0 0
Antwerpen
Country [37] 0 0
Belgium
State/province [37] 0 0
Brugge
Country [38] 0 0
Belgium
State/province [38] 0 0
Gent
Country [39] 0 0
Brazil
State/province [39] 0 0
Bahia
Country [40] 0 0
Brazil
State/province [40] 0 0
Parana
Country [41] 0 0
Brazil
State/province [41] 0 0
Rio Grande Do Sul
Country [42] 0 0
Brazil
State/province [42] 0 0
Sao Paulo
Country [43] 0 0
Brazil
State/province [43] 0 0
Rio De Janeiro
Country [44] 0 0
Brazil
State/province [44] 0 0
Sao paulo
Country [45] 0 0
Canada
State/province [45] 0 0
Alberta
Country [46] 0 0
Canada
State/province [46] 0 0
British Columbia
Country [47] 0 0
Canada
State/province [47] 0 0
Manitoba
Country [48] 0 0
Canada
State/province [48] 0 0
Nova Scotia
Country [49] 0 0
Canada
State/province [49] 0 0
Ontario
Country [50] 0 0
Canada
State/province [50] 0 0
Quebec
Country [51] 0 0
Canada
State/province [51] 0 0
Saskatchewan
Country [52] 0 0
Czechia
State/province [52] 0 0
Hradec Kralove
Country [53] 0 0
Czechia
State/province [53] 0 0
Prague
Country [54] 0 0
Czechia
State/province [54] 0 0
Praha 10
Country [55] 0 0
Denmark
State/province [55] 0 0
Aalborg
Country [56] 0 0
Denmark
State/province [56] 0 0
Aarhus C
Country [57] 0 0
Denmark
State/province [57] 0 0
Copenhagen
Country [58] 0 0
Denmark
State/province [58] 0 0
Odense C
Country [59] 0 0
Denmark
State/province [59] 0 0
Roskilde
Country [60] 0 0
France
State/province [60] 0 0
Cedex
Country [61] 0 0
France
State/province [61] 0 0
La Tronche
Country [62] 0 0
France
State/province [62] 0 0
Limoges
Country [63] 0 0
France
State/province [63] 0 0
Paris
Country [64] 0 0
Hong Kong
State/province [64] 0 0
Kowloon
Country [65] 0 0
Hong Kong
State/province [65] 0 0
Hong Kong
Country [66] 0 0
Hong Kong
State/province [66] 0 0
Tuen Mun
Country [67] 0 0
Hungary
State/province [67] 0 0
Budapest
Country [68] 0 0
Hungary
State/province [68] 0 0
Debrecen
Country [69] 0 0
Hungary
State/province [69] 0 0
Gyor
Country [70] 0 0
Hungary
State/province [70] 0 0
Pecs
Country [71] 0 0
Hungary
State/province [71] 0 0
Szeged
Country [72] 0 0
Italy
State/province [72] 0 0
Emilia-Romagna
Country [73] 0 0
Italy
State/province [73] 0 0
Lazio
Country [74] 0 0
Italy
State/province [74] 0 0
Alessandria
Country [75] 0 0
Italy
State/province [75] 0 0
Bologna
Country [76] 0 0
Italy
State/province [76] 0 0
Cagliari
Country [77] 0 0
Italy
State/province [77] 0 0
Cuneo
Country [78] 0 0
Italy
State/province [78] 0 0
Genova
Country [79] 0 0
Italy
State/province [79] 0 0
Milano
Country [80] 0 0
Italy
State/province [80] 0 0
Napoli
Country [81] 0 0
Italy
State/province [81] 0 0
Rionero In Volture
Country [82] 0 0
Italy
State/province [82] 0 0
Rome
Country [83] 0 0
Italy
State/province [83] 0 0
Rozzano
Country [84] 0 0
Italy
State/province [84] 0 0
Torrette Di Ancona
Country [85] 0 0
Japan
State/province [85] 0 0
Fukuoka-city
Country [86] 0 0
Japan
State/province [86] 0 0
Fukuoka
Country [87] 0 0
Japan
State/province [87] 0 0
Hiroshima-city
Country [88] 0 0
Japan
State/province [88] 0 0
Maebashi-city
Country [89] 0 0
Japan
State/province [89] 0 0
Nagoya
Country [90] 0 0
Japan
State/province [90] 0 0
Osaka Prefecture
Country [91] 0 0
Japan
State/province [91] 0 0
Sendai-city
Country [92] 0 0
Japan
State/province [92] 0 0
Chuo-ku
Country [93] 0 0
Japan
State/province [93] 0 0
Isehara-shi
Country [94] 0 0
Japan
State/province [94] 0 0
Koto-ku
Country [95] 0 0
Korea, Republic of
State/province [95] 0 0
Gyeonggi
Country [96] 0 0
Korea, Republic of
State/province [96] 0 0
Jeollanam-do
Country [97] 0 0
Korea, Republic of
State/province [97] 0 0
Seoul
Country [98] 0 0
Korea, Republic of
State/province [98] 0 0
Busan
Country [99] 0 0
Korea, Republic of
State/province [99] 0 0
Daegu
Country [100] 0 0
Korea, Republic of
State/province [100] 0 0
Incheon
Country [101] 0 0
Korea, Republic of
State/province [101] 0 0
Jeonju
Country [102] 0 0
Norway
State/province [102] 0 0
Bergen
Country [103] 0 0
Norway
State/province [103] 0 0
Oslo
Country [104] 0 0
Poland
State/province [104] 0 0
Gdansk
Country [105] 0 0
Poland
State/province [105] 0 0
Katowice
Country [106] 0 0
Poland
State/province [106] 0 0
Krakow
Country [107] 0 0
Poland
State/province [107] 0 0
L0dz
Country [108] 0 0
Poland
State/province [108] 0 0
Olsztyn
Country [109] 0 0
Poland
State/province [109] 0 0
Warszawa
Country [110] 0 0
Poland
State/province [110] 0 0
Wroclaw
Country [111] 0 0
Russian Federation
State/province [111] 0 0
Poselok Pesochny
Country [112] 0 0
Russian Federation
State/province [112] 0 0
Republic Of Bashkortostan
Country [113] 0 0
Russian Federation
State/province [113] 0 0
Republic Tatrstan
Country [114] 0 0
Russian Federation
State/province [114] 0 0
Moscow
Country [115] 0 0
Russian Federation
State/province [115] 0 0
Moskva
Country [116] 0 0
Russian Federation
State/province [116] 0 0
St.Petersburg
Country [117] 0 0
South Africa
State/province [117] 0 0
Gauteng
Country [118] 0 0
South Africa
State/province [118] 0 0
Kwa Zulu Natal
Country [119] 0 0
South Africa
State/province [119] 0 0
Bloemfontein
Country [120] 0 0
South Africa
State/province [120] 0 0
Cape Town
Country [121] 0 0
Spain
State/province [121] 0 0
Badalona
Country [122] 0 0
Spain
State/province [122] 0 0
Barcelona
Country [123] 0 0
Spain
State/province [123] 0 0
Marbella
Country [124] 0 0
Spain
State/province [124] 0 0
Pamplona
Country [125] 0 0
Spain
State/province [125] 0 0
Salamanca
Country [126] 0 0
Spain
State/province [126] 0 0
Santiago de Compostela
Country [127] 0 0
Spain
State/province [127] 0 0
Valencia
Country [128] 0 0
Taiwan
State/province [128] 0 0
Changhua City
Country [129] 0 0
Taiwan
State/province [129] 0 0
Chiayi County 613
Country [130] 0 0
Taiwan
State/province [130] 0 0
Tainan
Country [131] 0 0
Taiwan
State/province [131] 0 0
Taipei
Country [132] 0 0
Taiwan
State/province [132] 0 0
Taoyuan County
Country [133] 0 0
Turkey
State/province [133] 0 0
Ankara
Country [134] 0 0
Turkey
State/province [134] 0 0
Istanbul
Country [135] 0 0
Turkey
State/province [135] 0 0
Samsun
Country [136] 0 0
United Kingdom
State/province [136] 0 0
Cornwall
Country [137] 0 0
United Kingdom
State/province [137] 0 0
Scotland
Country [138] 0 0
United Kingdom
State/province [138] 0 0
Surrey
Country [139] 0 0
United Kingdom
State/province [139] 0 0
Wales
Country [140] 0 0
United Kingdom
State/province [140] 0 0
Birmingham
Country [141] 0 0
United Kingdom
State/province [141] 0 0
Canterbury
Country [142] 0 0
United Kingdom
State/province [142] 0 0
Exeter
Country [143] 0 0
United Kingdom
State/province [143] 0 0
Inverness
Country [144] 0 0
United Kingdom
State/province [144] 0 0
Leicester
Country [145] 0 0
United Kingdom
State/province [145] 0 0
Lincoln
Country [146] 0 0
United Kingdom
State/province [146] 0 0
Liverpool
Country [147] 0 0
United Kingdom
State/province [147] 0 0
London
Country [148] 0 0
United Kingdom
State/province [148] 0 0
Manchester
Country [149] 0 0
United Kingdom
State/province [149] 0 0
Norfolk
Country [150] 0 0
United Kingdom
State/province [150] 0 0
Northwood
Country [151] 0 0
United Kingdom
State/province [151] 0 0
Nottingham
Country [152] 0 0
United Kingdom
State/province [152] 0 0
Oxford
Country [153] 0 0
United Kingdom
State/province [153] 0 0
Romford
Country [154] 0 0
United Kingdom
State/province [154] 0 0
Southampton

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Takeda
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Seagen Inc.
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of
comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin
(ADCETRIS®) plus AVD (doxorubicin [Adriamycin], vinblastine, and dacarbazine; abbreviated
A+AVD) versus that obtained with ABVD (doxorubicin [Adriamycin],bleomycin, vinblastine, and
dacarbazine) for the frontline treatment of advanced classical Hodgkin lymphoma(HL)
Trial website
https://clinicaltrials.gov/ct2/show/NCT01712490
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Study Director
Address 0 0
Takeda
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries